Article Figures & Data
Figures
- FIG 1
Mean log10 CFU/ml versus time profiles for each drug at the highest concentration tested against the four E. coli strains. Aztreonam is shown at fCmax (A and C) and at 4× MIC (B and D). Ceftazidime and meropenem are shown at fCmax in all panels. Curves represent average concentrations from triplicate experiments.
- FIG 2
Mean log10 CFU/ml versus time profiles for each drug at the highest concentration tested against the four K. pneumoniae strains. (A to D) All drugs are shown at fCmax. Curves represent average concentrations from triplicate experiments.
- FIG 3
Mean log10 CFU/ml versus time profiles for each individual drug at the highest concentration tested that demonstrated no activity and triple-drug combinations against the four E. coli strains. (A to D) Ceftazidime-avibactam and meropenem-vaborbactam are shown at fCmax alone and in combination. (A and C) Aztreonam is shown at fCmax alone and in combination. Aztreonam is shown at 1× MIC (B) and at 0.25× MIC (D) alone and in combination. Curves represent average concentrations from triplicate experiments.
- FIG 4
Mean log10 CFU/ml versus time profiles for each individual drug at the highest concentration tested that demonstrated no activity and triple drug combinations against the four K. pneumoniae strains. (A to D) All drugs are shown alone and in combination at fCmax. Curves represent average concentrations from triplicate experiments.
Tables
- TABLE 1
Genotypic and phenotypic susceptibility of tested serine and NDM-producing E. coli and K. pneumoniae isolatesa
Supplemental material
- Supplemental file 1 -
Figure S1, Figure S2, Table S1, Table S2, Table S3, Table S4
PDF, 867K
- Supplemental file 1 -
